Resistance to Rituximab Therapy in Sjögren’s Syndrome
Author Information
Author(s): Quartuccio Luca, Fabris Martina, Moretti Massimo, Barone Francesca, Bombardieri Michele, Rupolo Maurizio, Lombardi Sandra, Pitzalis Costantino, Beltrami Carlo Alberto, Curcio Francesco, De Vita Salvatore
Primary Institution: University of Udine, Italy
Hypothesis
Does local BAFF overexpression contribute to resistance to rituximab therapy in Sjögren’s syndrome-related lymphoproliferation?
Conclusion
BAFF overexpression may contribute to resistance to rituximab therapy in Sjögren’s syndrome-related MALT lymphoma.
Supporting Evidence
- BAFF levels were high in the serum and salivary glands of the patient.
- Rituximab treatment did not improve the patient's symptoms.
- Persistent overexpression of BAFF was documented in the salivary gland tissue.
Takeaway
This study looks at a woman with Sjögren’s syndrome who didn't get better after treatment with rituximab because a substance called BAFF was too high in her body.
Methodology
The study involved monitoring BAFF levels and B-cell biomarkers in a patient with Sjögren’s syndrome and MALT lymphoma before and after rituximab treatment.
Limitations
The study is based on a single case, limiting the generalizability of the findings.
Participant Demographics
51-year-old woman with primary Sjögren’s syndrome and mixed cryoglobulinaemia type II.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website